ALUMIS INC.

ALMS · Nasdaq · SIC 2834: Pharmaceutical Preparations
42
SEC Filings

Business Summary

PARTI Overview Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words allumerFrench for illuminateand immunisLatin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: envudeucitinib (envu), formerly known as ESK-001, a second-generation...

Next Earnings

Q2 FY2026 — expected 2026-09-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionALMSdiscussed_in_filing Cybersecurity
topic_mentionALMSdiscussed_in_filing Trusted Computing
topic_mentionALMSdiscussed_in_filing Blockchain & Crypto
topic_mentionALMSdiscussed_in_filing Regulation
topic_mentionALMSdiscussed_in_filing Healthcare & Bio
topic_mentionALMSdiscussed_in_filing Platform & Ecosystem
topic_mentionALMSdiscussed_in_filing Sovereign & Government
topic_mentionALMSdiscussed_in_filing Cybersecurity
topic_mentionALMSdiscussed_in_filing Trusted Computing
topic_mentionALMSdiscussed_in_filing Blockchain & Crypto
topic_mentionALMSdiscussed_in_filing Regulation
topic_mentionALMSdiscussed_in_filing Healthcare & Bio
topic_mentionALMSdiscussed_in_filing Platform & Ecosystem
topic_mentionALMSdiscussed_in_filing Sovereign & Government
topic_mentionALMSdiscussed_in_filing Cybersecurity
topic_mentionALMSdiscussed_in_filing Trusted Computing
topic_mentionALMSdiscussed_in_filing Blockchain & Crypto
topic_mentionALMSdiscussed_in_filing Regulation
topic_mentionALMSdiscussed_in_filing Healthcare & Bio
topic_mentionALMSdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001847367-26-000006EDGAR130K words
2025-03-192024-12-310001847367-25-000012EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001847367-25-000050EDGAR88K words
2025-08-132025-06-300001847367-25-000041EDGAR—
2025-05-142025-03-310001847367-25-000028EDGAR—
2024-11-132024-09-300001847367-24-000005EDGAR—
2024-08-132024-06-300001558370-24-012081EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001104659-26-036386EDGAR4K words
2026-03-190001847367-26-000004EDGAR—
2026-01-090001104659-26-002265EDGAR—
2026-01-060001104659-26-001073EDGAR—
2026-01-020001104659-26-000197EDGAR—
2025-11-130001847367-25-000048EDGAR—
2025-09-030001104659-25-086612EDGAR—
2025-08-130001847367-25-000039EDGAR—
2025-08-040001104659-25-073628EDGAR—
2025-05-210001104659-25-051338EDGAR—

42 total filings indexed. 25 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001847367
TickerALMS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: cc48786f8e56a6f9a9976d0a3fdc5d8c5437cb007590e87efc164fb1c8b294e6
parent: 15d41881d6883217ac1414ea75555b6983240c5826a691a338243e1fd6ca4ebc
content hash: ed50d9a6cb4a7901248a354dd2fa40988e2a584d728d61a9163232fae877580a
signed: 2026-04-13T04:43:35.790Z
sources: 7 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf